Tissue Regenix Group PLC Annual Report & Accounts and Notice of AGM (4540H)

TIDMTRX

RNS Number : 4540H

Tissue Regenix Group PLC

19 May 2014

Tissue Regenix Group plc

Annual Report & Accounts and Notice of Annual General Meeting

YORK, 19th May 2014 - Tissue Regenix Group plc (AIM:TRX) ("Tissue Regenix" or "the Group"), the regenerative medical devices company, today announces that the Annual Report and Accounts for the year ended 31 January 2014 have been distributed to shareholders together with the Notice of the Annual General Meeting ("AGM"). The AGM will be held at DLA Piper UK LLP, Princes Exchange, Princes Square, Leeds LS1 4BY on 27 June 2014 at 10am. A copy of the Annual Report and Accounts is available on the Group's website at: http://www.tissueregenix.com/.

Enquiries

 
 Tissue Regenix Group 
  plc                       +44 (0)1904 435 176 
 Antony Odell, Chief 
  Executive Officer 
  Ian Jefferson, Chief 
  Financial Officer 
 
 Jefferies International 
  Ltd.                      +44 (0)20 7029 8000 
 Simon Hardy 
  Harry Nicholas 
 
 Newgate Communications     +44 (0)20 7680 6550 
 Andrew Jones 
  Stephanie Dobbs

About Tissue Regenix

Tissue Regenix is a leading medical devices company in the field of regenerative medicine. The company's patented decellularisation ('dCELL(R)') technology removes DNA and other cellular material from animal and human tissue leaving an acellular tissue scaffold which is not rejected by the patient's body which can then be used to repair diseased or worn out body parts. The potential applications of this process are diverse and address many critical clinical needs such as vascular disease, heart valve replacement and knee repair.

Tissue Regenix was formed in 2006 when it was spun-out from the University of Leeds. The company commercialises academic research conducted by our partners around the World.

In November 2012 Tissue Regenix Group plc set up a subsidiary company in the United States- 'Tissue Regenix Wound Care Inc.', as part of its commercialisation strategy for its dCELL(R) technology platform.

This information is provided by RNS

The company news service from the London Stock Exchange

END

ACSQKCDDCBKKPPD

Tissue Regenix (LSE:TRX)
Historical Stock Chart
From Aug 2024 to Sep 2024